Latest (38) Full Text Articles (547) Article Summary

print mdlinx article: Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis

email mdlinx article: Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis

save mdlinx article to my library: Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis

Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis Full Text
Amgen, 04/06/2012

UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis.

► Click here to access Full Text, PubMed, Publisher and related articles...

Currently, there are no available articles.

Your Unread Messages in Pharma News

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Patients 50+ may be at increased risk for pneumococcal disease. Learn what you can do.

What are your treatment options for patients with metastatic colorectal cancer? www.mCRCTreatmentOption.com

Most Popular Pharma News Articles

Last month's top read Top Articles of 2012

Indexed Journals in Pharma News: U.S.Pharmacist, FDA Drug Alerts, Pharmiweb more

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis Full Text Amgen, 04/06/2012

Most Popular Pharma News Articles

Other Topics in Pharma News

Ucb and amgen initiate sclerostin antibody phase 3 program in patients with postmenopausal osteoporosis Full Text
Amgen, 04/06/2012